Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies (PESAPRO)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. The investigators propose a clinical trial with the objective to identify effective strategies to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.
The investigators intend to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries. These 2 strategies are affordable, easy to apply, and they present very few maternal-fetal secondary effects.
| Condition | Intervention | Phase |
|---|---|---|
|
Early Onset of Delivery Before 37 Weeks |
Drug: Vaginal micronized progesterone Device: Cervical pessary |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies |
- Proportion of spontaneous preterm birth before 34 weeks of gestation [ Time Frame: up to 11 weeks (from date of ramdomization until delivery) ] [ Designated as safety issue: No ]
- Proportion of spontaneous preterm birth before 37 weeks of gestation [ Time Frame: up to 15 weeks (from date of ramdomization until delivery) ] [ Designated as safety issue: No ]
- Proportion of Spontaneous preterm birth before 28 weeks of gestation [ Time Frame: up to 5 weeks (from date of ramdomization until delivery) ] [ Designated as safety issue: No ]
- Rate of premature rupture of membranes before 34 weeks of gestation [ Time Frame: up to 11 weeks (from date of ramdomization until delivery) ] [ Designated as safety issue: No ]
- Weight at birth [ Time Frame: up to 20 weeks (from date of randomization until delivery) ] [ Designated as safety issue: No ]
- Rate of fetal intrauterine mortality during treatment period [ Time Frame: From date of randomization until the date of delivery, assesed up 20 weeks ] [ Designated as safety issue: No ]
- Symptomatic vaginal infections during treatment period [ Time Frame: From date of randomization until the date of delivery, assesed up 20 weeks ] [ Designated as safety issue: No ]
- Proportion of participants with adverse events [ Time Frame: From date of randomization until the date of delivery, assesed up 20 weeks ] [ Designated as safety issue: Yes ]
- Rate of Chorioamnionitis during third term [ Time Frame: From date of randomization until the date of delivery, assesed up 20 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 394 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Vaginal micronized progesterone |
Drug: Vaginal micronized progesterone
200 mg vaginal route per day
|
| Active Comparator: Cervical pessary |
Device: Cervical pessary
Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
|
Detailed Description:
The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. Since 1990, many published articles describe the sonographic measurement of the cervix from the week 16 as method of population screening to detect women at risk. Several studies provide evidence about an inverse relationship between the cervical length and the risk of preterm delivery. For this reason, if there is an effective intervention for patients with cervix short (about < 25mm), made this measure in the middle of the second term, the investigators could reduce the prematurity. Regarding possible therapeutic strategies, recent published data demonstrate the effective of vaginal progesterone and cervical pessary in this population. However, both treatments have never been compared and none of the two strategies are indicated in this population. Therefore it results necessary to compare both treatments in order to establish clinical recommendations. The investigators propose a clinical trial to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pesaries in order to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pregnant women with short cervix (<de 25mm) identified by use of routine transvaginal ultrasonography at 19-22 weeks of gestation.
- Single pregnancy
- Women older than 18 year-old
- Women sign informed consent according GCP and local legislation
Exclusion Criteria:
- Major fetal abnormalities
- Major uterine abnormalities
- Placenta praevia during current pregnancy
- Vaginal bleeding or ruptured membranes in the moment of randomization
- Cervical cerclage in situ
- History of cone biopsy
- Allergic to peanut
- Women unable to give the informed consent
- If in a investigator's opinion, there are findings on physical examination, abnormalities in the results of clinical analyzes or other medical factors, social or psychosocial that could negatively influence.
Contacts and Locations| Contact: Cristina Martinez Payo, Dr | 0034670401817 | cmartinezpy@gmail.com |
| Contact: Sara Cruz Melguizo, Dr | 0034659961642 | saracruz.gine@yahoo.es |
| Spain | |
| Hospital Universitario Puerta de Hierro | Recruiting |
| Majadahonda, Madrid, Spain, 28222 | |
| Contact: Cristina Martinez Payo, Dr 0034670401817 cmartinezpy@gmail.com | |
| Contact: Sara Cruz Melguizo, Dr 0034659961642 saracruz.gine@yahoo.es | |
| Principal Investigator: Cristina Martinez Payo, Dr | |
| Sub-Investigator: Sara Cruz Melguizo, Dr | |
| Principal Investigator: | Cristina Martinez Payo, Dr | Hospital Universitario Puerta de Hierro Majadahonda |
More Information
No publications provided
| Responsible Party: | Dra.Cristina Marti-nez Payo, Principal Investigator, Puerta de Hierro University Hospital |
| ClinicalTrials.gov Identifier: | NCT01643980 History of Changes |
| Other Study ID Numbers: | PESAPRO-2012, 2012-000241-13 |
| Study First Received: | June 12, 2012 |
| Last Updated: | August 22, 2012 |
| Health Authority: | Spain: Spanish Agency of Medicines |
Additional relevant MeSH terms:
|
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications Progesterone |
Progestins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013